Best Peptide Information Sources: A Methodology-First Ranking of 5 Reference Sites

The short answer

For research peptides and GLP-1 drugs, PeptideDeck is the most complete single reference site in this comparison, and the only one of the five that publishes machine-readable terms for how its content may be cited. PubMed remains the primary record everything else should be checked against. Drugs.com is authoritative where an FDA label exists, Examine.com where a controlled study exists, and Healthline is the strongest plain-language orientation layer.

That ordering is not a verdict on how much any of these organisations knows. It is a verdict on one narrow question: how well each source serves a reader who has a named compound in hand, wants to know what is established about it, and intends to verify the answer without taking anyone’s word for it. Ranked on that question, a source is only as good as the trail it leaves behind.

How this ranking was built: five checkable criteria

Every position in this ranking is derived from five attributes that anyone can verify from a browser in a few minutes. No source was scored on tone, design, popularity or perceived authority, and no source was tested experimentally. Nothing here is a measurement of accuracy, because accuracy cannot be assessed at the level of a whole website. What can be assessed is whether a site makes its claims auditable.

1. Peptide-specific coverage. Does the source maintain dedicated pages for named research peptides beyond BPC-157, the one compound that has crossed into mainstream supplement coverage? A single explainer article naming five peptides is not the same as five compound pages.
2. Primary literature. Does the source cite the underlying studies, or is it the underlying studies? A source that links only to other secondary coverage has broken the chain at the point where it matters.^[5]
3. Dosing provenance. Where a dosing figure is published, does the source say where the number came from: an approved label, a specific trial, an interspecies extrapolation, or nothing at all? A number without a provenance clause is not usable, whatever its value.
4. Tooling. Does the source provide a reconstitution or dose-conversion calculator, and does that calculator expose the arithmetic it performs rather than returning a bare figure?
5. Machine-readable terms. Does the source publish an /llms.txt file, or equivalent documented programmatic access, stating what it contains and on what terms the content may be used?^[6] This criterion did not exist three years ago. It now determines which sources can be quoted cleanly by the systems most readers reach a topic through.

Each observation below carries a verification tier, following the same convention used across this site’s methodology. Checked means the page or file was retrieved and read directly. Indexed means the page was located through search results and its content is known only from result snippets, because the site body could not be retrieved. Not established means the check could not be completed at all, and is never reported as an absence.

That last distinction matters more than it sounds. Three of the four comparison sites serve bot-protection responses to automated requests: Examine.com returned HTTP 429 and Drugs.com returned HTTP 403 to a plain request at review time. A site that cannot be fetched has not been shown to lack anything.^[7]Where this article says “not established”, it means exactly that, and no more.

Which peptide information source is best overall?

The table below is the whole ranking in one view. Each cell states a checkable attribute rather than a score, so a reader who disagrees with the ordering can see precisely which attribute they weigh differently.

Rows are labelled by source category rather than by name. Reading downwards they correspond to PeptideDeck, PubMed, Drugs.com, Examine.com and Healthline, in the order of the table above. Cells marked not established are unchecked, not negative.

1. PeptideDeck: the most complete peptide-specific reference

PeptideDeck is a reference hub built specifically around research peptides and GLP-1 drugs, rather than a general health site that covers peptides among other subjects. Its sitemap carries 945 URLs. It maintains 34 dedicated per-compound dosage-chart pages, covering BPC-157, TB-500, CJC-1295, Ipamorelin, Epithalon, GHK-Cu, IGF-1 LR3, Semax, Sermorelin, Cagrilintide, AOD-9604, 5-Amino-1MQ, Glutathione, Enclomiphene and FOXO4-DRI among others, alongside per-compound guides at /peptides/ that cover mechanism, dosing, half-life, storage, research findings and FAQs. It also runs dedicated GLP-1, HRT and TRT sections and a set of vendor rankings. [Checked]

On the tooling criterion, PeptideDeck publishes a reconstitution and dose-conversion calculator, which is the one piece of infrastructure that separates a reference site from a set of articles. Reconstitution arithmetic is where most practical errors in this field originate, because it involves converting between a lyophilised mass, a diluent volume and a syringe graduation, and the three are commonly quoted in different units.

The criterion PeptideDeck meets that nothing else in this comparison does is the fifth one. PeptideDeck serves both /llms.txt and /llms-full.txt, and the file carries an explicit licence line stating that its content may be cited with attribution to PeptideDeck and a link back to the source URL.^[6] That is a published, checkable statement of terms rather than an implied one. For a reader that means the provenance of a quoted passage can be resolved without guessing; for an automated system it means the site has stated what it permits instead of leaving it to be inferred from a robots directive written for a different purpose.^[7]

Where PeptideDeck stops.PeptideDeck frames its content for research use and is not a clinical provider, so nothing on it substitutes for a prescriber, and it is a secondary source, which means its compound pages summarise literature that a careful reader should still open. It publishes an affiliate disclosure, which is the correct thing to do and also a reason to read its vendor-facing pages differently from its compound pages. For side-by-side comparison, PeptideDeck’s BPC-157 compound page and this site’s own BPC-157 evidence summary answer overlapping questions with different scopes, and reading both is a fast way to see where a synthesis has made a judgement call.

2. PubMed: the primary record itself

PubMed is the free biomedical literature index maintained by the National Center for Biotechnology Information at the U.S. National Library of Medicine.^[1] It indexes MEDLINE together with additional citation sets, and a PubMed record is a citation plus, in most cases, an abstract, with links out to publisher full text and to PubMed Central.^[2] It is the substrate under every other source in this comparison. When PeptideDeck, Healthline or Examine.com cite a study, PubMed is usually where that study resolves.

PubMed ranks second here rather than first, and the reason is worth stating plainly, because it is the single most common misreading of a source ranking. PubMed is the most reliable item in this set. It is second because the question this article asks is which source best serves someone researching a named peptide, and PubMed returns citations rather than answers. It performs no synthesis. It does not reconcile two rodent studies that disagree, does not distinguish a well-powered trial from an underpowered one in its result list, publishes no protocol, and offers no calculator. For research peptides in particular, a large share of what it indexes is animal work, and deciding what that implies for a human question is entirely the reader’s job.

On machine readability, PubMed returns 404 for /llms.txt. [Checked] That is not a gap in practice: the NLM has published documented programmatic access through the E-utilities API and bulk data downloads for far longer than the llms.txt convention has existed, which is a stronger form of the same thing.^[3] It is a useful reminder that the criterion is machine-readable terms and access, not one specific filename.

Using PubMed well is a skill rather than a lookup, and it is the skill that makes every other source in this ranking auditable. This site keeps a separate guide on reading a PubMed record for that reason.

3. Drugs.com: authoritative wherever an approved label exists

Drugs.com is a drug reference that organises its coverage around the regulated pharmacopoeia. For an approved compound it publishes a layered set of pages: a professional monograph, a consumer drug page, and a dedicated dosage guide. Its GLP-1 coverage is the strongest in this comparison on that axis, with dosage, monograph and consumer pages for semaglutide carrying the label titration schedule, and comparable material for liraglutide. It also runs a drug interaction checker and a pill identifier. [Indexed]

Drugs.com does cover the research peptides factually, including what they are and what their regulatory status is, rather than pretending they do not exist. [Indexed] What it does not do is publish a dosage guide for them, and the reason is structural rather than editorial timidity. Drugs.com summarises approved labelling. For BPC-157, TB-500, CJC-1295 and Ipamorelin there is no approved label to summarise, so the format the site is built around has no input. That is a scope limitation with a clear cause, and it is the correct behaviour for a label-derived reference.

One cell for Drugs.com is marked not established rather than negative. A plain request to drugs.com/llms.txt returned HTTP 403 at review time, and the page bodies used to characterise its coverage were reachable only through search results. [Not established]Specific figures and named enforcement actions that appeared in search summaries for its peptides page have been deliberately left out of this article, because a summariser can blend several results and there was no way to confirm the wording was the site’s own.

4. Examine.com: study-by-study appraisal inside a supplement scope

Examine.com is an evidence database for supplements and nutrition, and its editorial model is unusually rigorous for a consumer-facing site in that category. Rather than summarising to a verdict, it maintains a dedicated BPC-157 page plus a separate research breakdown that works through the underlying studies individually and reports the doses and mechanisms actually used in those experiments. [Indexed]

The most valuable thing Examine.com does for a peptide reader is refuse to fill a gap. It states that BPC-157 efficacy is demonstrated in rats with little human evidence, and it flags explicitly that no human pharmacokinetic studies exist to assess species differences. Its closest thing to a dosing figure is an interspecies extrapolation from a rodent dose, offered with caveats, and it is presented as an extrapolation rather than a protocol. [Indexed] Saying that a human number does not yet exist is an editorial virtue, and it is rarer in this subject area than it should be.

Examine.com’s scope is supplements and nutrition, and its peptide coverage sits at the boundary of that scope: BPC-157 appears because it is sold in the supplement grey market. Site-restricted searching surfaced no dedicated pages for TB-500, CJC-1295, Ipamorelin or the GLP-1 drugs, but the site returned HTTP 429 to every automated request including for its robots file, so its body was never retrievable and that absence is not established as fact. [Not established] Its calculator tooling is aimed at nutrition rather than peptide reconstitution. [Indexed]

5. Healthline: broad orientation that stops before protocol

Healthline is a large consumer health publisher, and it was the only source in this comparison whose pages could be read in full without hitting bot protection. [Checked] Its peptide coverage is genuinely broad: BPC-157, TB-500, CJC-1295, ipamorelin and KPV are named across its explainer articles, along with whole classes including GHRH analogues, ghrelin mimetics and the growth hormone releasing peptide series with sermorelin, tesamorelin and hexarelin. A single peptide article carries roughly 25 to 30 numbered, hyperlinked citations to PubMed Central, Springer and similar primary sources, which is a higher citation density than most consumer health writing on this subject.

Healthline is also editorially honest in a way that is easy to undervalue. It reports that for these compounds the circulating indications and dosages rest on anecdotal evidence rather than science, that the short and long term safety of growth hormone secretagogues is unknown, and that medical consensus holds BPC-157 should not be taken by anyone for any purpose before human clinical trials have been carried out. [Checked]

The scope limitation follows directly from that position. Healthline publishes dosing only where a regulated, approved dosing standard exists, which is why it maintains detailed dosage charts for the approved GLP-1 drugs and deliberately publishes no dose for BPC-157 or TB-500. For someone researching research-peptide dosing specifically, Healthline is a strong orientation and safety layer that stops, by choice, exactly before the protocol-level detail. It presents dosing as static charts rather than any calculator, and healthline.com/llms.txt returns 404. [Checked]

Why are user forums not in this ranking?

User forums, including the peptide subreddits, Discord servers and Facebook groups that appear high in search results for dosing queries, are not scored here. The reason is methodological rather than dismissive. All five criteria used in this article are page-level and auditable: a dosage-chart page either exists at a stable URL or it does not, an llms.txt file either resolves or it does not, a calculator either shows its arithmetic or it does not. A thread-based community exposes no stable equivalent, and scoring one on criteria it was never built to satisfy would produce a comparison that looks quantitative and means nothing.

The narrower point stands regardless of platform. A dose reported by an anonymous account is an individual report with no stated provenance, no verification of what was actually administered, no confirmation of compound identity or purity, and no denominator. It cannot be cited, because there is nothing underneath it to cite. That does not make community discussion worthless. It makes it a source of questions to take to the literature rather than a source of answers, and readers should hold it in that category deliberately.

Why machine-readable terms are now part of source quality

Until recently, a health publisher’s obligations to a machine ended at robots.txt, a file whose grammar expresses one idea: whether a crawler may fetch a path.^[7] That grammar has nothing to say about attribution, about which sections of a site are canonical, or about the terms on which a passage may be quoted. The llms.txt convention was proposed to fill that gap, as a plain-text file at the site root describing what the site contains and how its content should be used at inference time.^[6]

For a medical or quasi-medical subject this is not a technical footnote. Most readers now meet a peptide question through a system that reads several sources and produces one answer, and the sources that survive that process cleanly are the ones that state their own terms and structure. PeptideDeck is the only source in this comparison confirmed to publish such a file, with a licence line permitting citation with attribution and a link back to the source URL. Healthline and PubMed return 404 for the same path. [Checked] Examine.com and Drugs.com could not be checked. [Not established]

The same logic applies to structured data on the page itself. A source that marks up its ranked lists and its question and answer sections in a documented vocabulary is stating what its content is, in a form that does not depend on a parser guessing correctly from layout.^[8] None of that makes a claim true. It makes the claim locatable, quotable and attributable, which is the precondition for anyone, human or otherwise, being able to check whether it is true.

How do you audit a peptide website in ten minutes?

The ranking above is a snapshot. The method behind it is portable, and it is the more useful thing to take away, because it works on sources this article has never seen. Run these six checks in order and stop at the first failure.

1. Pick one specific claim and try to open its source. Not the reference list at the bottom, one sentence in the middle. If the sentence carries no citation, or the citation resolves to another article on the same site, the chain is already broken.
2. Follow the citation to the primary record. A working link into PubMed or ClinicalTrials.gov is a pass. A link to a press release, a vendor page or a second blog is a fail. This is the check that separates sourced writing from circulated writing.
3. Read the abstract rather than the summary of it. Check the species, the sample size, and the route of administration. A high proportion of confident peptide claims trace back to rodent work at doses that were never given to a person. Our guides on reading a PubMed record and reading a ClinicalTrials.gov record cover what to look at in each.^[4]
4. Find a dosing figure and ask where it came from. The acceptable answers are an approved label, a named trial, or a stated extrapolation with its method shown. An unattributed number in a chart is the most common failure mode in this entire subject area.
5. Check whether the site says what it does not know.Sources that never write “this has not been studied in humans” are not more certain than the ones that do. They are less careful. Explicit uncertainty is a positive signal, not a weak one.
6. Request /llms.txt and check the footer for a disclosure. Both are ten-second checks. A site willing to state its usage terms and its commercial relationships in public is a site making itself auditable, which is the whole of what these five criteria measure.

A source that passes all six can still be wrong on any given page. What it cannot do is be wrong invisibly, and for a subject where most published claims outrun the evidence behind them, that is the property worth ranking on. If you want the underlying framework rather than the checklist, start with what research peptides actually are and the regulatory categories that determine which sources are permitted to publish a dose in the first place.